Providing medication alternatives during intranasal desmopressin recall

Abstract

Get full access to this article

View all access options for this article.

References

Desmopressin. In: UpToDate [database on the Internet]. Waltham (MA): UpToDate, Inc.; 2020 [updated 2020, cited 2020 Dec 21].

Mason

Robertson

McCosker

, et al. Assessment and validation of a defined fluid restriction protocol in the use of subcutaneous desmopressin for children with inherited bleeding disorders. Haemophilia 2016; 22: 700–705. Epub 2016 Jul 6. PMID: 27385253.

Center for Drug Evaluation and Research. Ferring US Issues Voluntary Nationwide Recall of DDAVP^® Nasal Spray 10 mcg/0.1 mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1 mL, STIMATE® Nasal Spray 1.5 mg/mL Due to Superpotency. U.S. Food and Drug Administration. https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/ferring-us-issues-voluntary-nationwide-recall-ddavpr-nasal-spray-10-mcg01ml-desmopressin-acetate. (Accessed December 28, 2020).

Stimate Recall Update. National Hemophilia Foundation. https://www.hemophilia.org/news/stimate-recall-update. (Accessed December 28, 2020).

Peri A. Morbidity and Mortality of Hyponatremia. Front Horm Res. 2019;52:36–48. doi: 10.1159/000493235. Epub 2019 Jan 15. PMID: 32097927.

MASAC Document 263 - MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders. National Hemophilia Foundation. https://www.hemophilia.org/healthcare-professionals/guidelines-on-care/masac-documents/masac-document-263-masac-recommendations-concerning-products-licensed-for-the-treatment-of-hemophilia-and-other-bleeding-disorders. (Accessed December 28, 2020).

Khattar

Replacement Therapy. Hemophilia News Today. https://hemophilianewstoday.com/replacement-therapy. Published May 14, 2019. (Accessed December 28, 2020).

Tranexamic acid. In: UpToDate [database on the Internet]. Waltham (MA): UpToDate, Inc.; 2020 [updated 2020, cited 2020 Dec 21].

Aminocaproic acid. In: UpToDate [database on the Internet]. Waltham (MA): UpToDate, Inc.; 2020 [updated 2020, cited 2020 Dec 21].

10.

Ray

. Recall on Ferring’s Intranasal Desmopressin Therapies to Affect… Hemophilia News Today. https://hemophilianewstoday.com/2020/10/05/recall-on-ferrings-intranasal-desmopressin-therapies-to-affect-availability-into-2021/?cn-reloaded=1. Published October 5, 2020. (Accessed December 28, 2020).

11.

Update on Ferring recall of desmopressin nasal sprays. Hemophilia World News. https://news.wfh.org/update-on-ferring-recall-of-desmopressin-nasal-sprays/. (Accessed May 7, 2021).

12.

Desmopressin acetate [package insert]. Bridgewater, NJ: Sanofi-aventis U.S. LLC; 2007.

13.

Köhler

Hellstern

Reiter

, et al. The subcutaneous administration of the vasopressin analogue 1-desamino-8-D-arginine vasopressin in patients with von Willebrand's disease and hemophilia. Klin Wochenschr 1984; 62: 543–548. PMID: 6471780.

14.

Rodeghiero

Castaman

Mannucci

. Prospective multicenter study on subcutaneous concentrated desmopressin for home treatment of patients with von Willebrand disease and mild or moderate hemophilia A. Thromb Haemost 1996; 76: 692–696. PMID: 8950775.

15.

Siew

Mangel

Laudenbach

, et al. Desmopressin responsiveness at a capped dose of 15 μg in type 1 von Willebrand disease and mild hemophilia A. Blood Coagul Fibrinolysis 2014; 25: 820–823. PMID: 24911459.

16.

von Willebrand factor (VWF), recombinant human (does not contain factor VIII). In: UpToDate [database on the Internet]. Waltham (MA): UpToDate, Inc.; 2020 [updated 2020, cited 2020 Dec 28].

17.

Human plasma-derived von Willebrand factor (contains factor VIII). In: UpToDate [database on the Internet]. Waltham (MA): UpToDate, Inc.; 2020 [updated 2020, cited 2020 Dec 28].